Prime Medicine, Inc.
PRME
$1.24
$0.000.00%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -17.74% | -1.53% | 24.49% | 22.33% | 42.66% |
| Gross Profit | 23.01% | 2.04% | -24.49% | -20.41% | -42.66% |
| SG&A Expenses | -5.98% | 34.40% | 18.23% | 21.91% | 35.94% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -14.92% | 5.79% | 23.01% | 22.23% | 40.99% |
| Operating Income | 18.92% | -5.39% | -23.01% | -20.75% | -40.99% |
| Income Before Tax | 35.60% | -3.35% | -30.95% | -15.22% | -66.32% |
| Income Tax Expenses | -- | -- | -532.26% | 166.34% | 100.00% |
| Earnings from Continuing Operations | 35.60% | -3.57% | -30.53% | -16.15% | -67.10% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 35.60% | -3.57% | -30.53% | -16.15% | -67.10% |
| EBIT | 18.92% | -5.39% | -23.01% | -20.75% | -40.99% |
| EBITDA | 20.25% | -4.88% | -22.64% | -20.64% | -40.94% |
| EPS Basic | 54.51% | 20.58% | 0.92% | 0.97% | -29.73% |
| Normalized Basic EPS | 44.11% | 19.39% | 6.33% | -5.30% | -14.52% |
| EPS Diluted | 54.51% | 20.58% | 0.92% | 0.97% | -29.73% |
| Normalized Diluted EPS | 44.11% | 19.39% | 6.33% | -5.30% | -14.52% |
| Average Basic Shares Outstanding | 41.59% | 30.40% | 31.75% | 17.29% | 24.63% |
| Average Diluted Shares Outstanding | 41.59% | 30.40% | 31.75% | 17.29% | 24.63% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |